Grünenthal Acquires US-Based Valinor Pharma for $250 Million
Grünenthal acquired Valinor Pharma and its product Movantik (naloxegol) for $250 million
Movantik is an oral treatment for opioid-induced constipation (OIC) in adults with chronic non-cancer pain
The acquisition expands Grünenthal's portfolio and strengthens its presence in the US market
Movantik generated over $200 million in gross US sales in 2023
With this deal, Grünenthal now owns global rights to Movantik/Moventig (except Canada)
This continues Grünenthal's strategy of growth through acquisitions, having invested over €2 billion in M&A since 2017
The acquisition aligns with Grünenthal's focus on pain management and related diseases
It furthers Grünenthal's goal of expanding its commercial footprint in the United States